CRF receptor autoradiography in antidepressant-treated rats
| Brain Region | Saline | Fluoxetine | Reboxetine | Venlafaxine | Tranylcypromine |
|---|---|---|---|---|---|
| CRF1 | |||||
| Frontal cortex | 100 ± 10 (6) | 89 ± 10 (6) | 105 ± 5 (7) | 82 ± 10 (6) | 90 ± 11 (7) |
| Parietal cortex | 100 ± 10 (8) | 109 ± 10 (7) | 92 ± 7 (8) | 84 ± 8 (7) | 93 ± 8 (6) |
| Basolateral amygdala | 100 ± 14 (8) | 110 ± 8 (7) | 86 ± 9 (8) | 98 ± 11 (9) | 90 ± 10 (8) |
| Centromedial amygdala | 100 ± 15 (8) | 109 ± 8 (7) | 80 ± 10 (8) | 83 ± 12 (8) | 100 ± 9 (8) |
| CRF2 | |||||
| Lateral septum | 100 ± 4 (5) | 102 ± 4 (8) | 95 ± 5 (8) | 98 ± 4 (8) | 86 ± 4 (7) |
| Ventromedial hypothalamus | 100 ± 4 (9) | 105 ± 9 (7) | 108 ± 9 (8) | 110 ± 5 (8) | 95 ± 10 (7) |
| Centromedial amygdala | 100 ± 8 (9) | 118 ± 7 (7) | 117 ± 15 (8) | 120 ± 7 (8) | 107 ± 9 (8) |
Rats were pretreated for 26 days with saline, venlafaxine (25 mg/kg/day), reboxetine (6.5 mg/kg/day), fluoxetine (4 mg/kg/day in 12% DMSO), or tranylcypromine (1.85 mg/kg/day). Subtype-specific CRF receptor binding was determined in the brain regions listed using [125I-Tyr0]-sauvagine autoradiography. Results are given as mean percentage of control ± S.E.M. (n).